First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

被引：0
|
作者：
Weili Sun
Huaying Liu
Young Kim
Nicole Karras
Anna Pawlowska
Debbie Toomey
Wade Kyono
Paul Gaynon
Joseph Rosenthal
Anthony Stein
机构：
[1] City of Hope National Medical Center,Department of Pediatrics
[2] Southern Medical University,Department of Pediatrics, Nanfang Hospital
[3] City of Hope National Medical Center,Department of Pathology
[4] University of Hawaii,Department of Pediatrics, Kapiolani Medical Center for Women and Children
[5] University of Southern California,Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles
[6] City of Hope National Medical Center,Department of Hematology and Hematopoietic Cell Transplantation
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
Pediatric; BPDCN; SL-401; Targeted therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123
    Zanotta, Serena
    Galati, Domenico
    De Filippi, Rosaria
    Pinto, Antonio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
  • [32] Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing.
    Pemmaraju, Naveen
    Lane, Andrew A.
    Sweet, Kendra Lynn
    Stein, Anthony Selwyn
    Vasu, Sumithira
    Blum, William G.
    Rizzieri, David
    Wang, Eunice S.
    Duvic, Madeleine
    Chen, Janice
    Shemesh, Shay
    McDonald, Peter
    Brooks, Christopher
    Kantarjian, Hagop M.
    Konopleva, Marina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Clinical and preclinical activity of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk of hematologic malignancies, against blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Frankel, Arthur E.
    Woo, Jung Hee
    Mauldin, Jeremy Preston
    Carraway, Hetty Eileen
    Frankfurt, Olga
    Forman, Stephen J.
    Brooks, Christopher
    Bergstein, Ivan
    Cirrito, Thomas
    Rowinsky, Eric K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Blastic plasmacytoid dendritic cell neoplasm: A clinicopathological diagnostic dilemma report of three cases with review of literature
    Purkait, Suvendu
    Gupta, Sanjeev
    Bakhshi, Sameer
    Mallick, Saumyaranjan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (09) : S471 - S474
  • [35] Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-Azacytidine
    Laribi, Kamel
    Denizon, Nathalie
    Ghnaya, Habib
    Atlassi, Mustapha
    Besancon, Anne
    Pineau-Vincent, Fabienne
    Gaulard, Philippe
    Petrella, Tony
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (01) : 81 - 85
  • [36] CD123+ Plasmacytoid Dendritic Cells from Systemic Sclerosis Patients Are Susceptible to the Cytotoxic Activity of Tagraxofusp, a CD123-Targeted Therapy
    Lindsay, Ross
    Chen, Janice
    Spiera, Robert
    Gordon, Jessica
    Kioon, Marie-Dominique Ah
    Barrat, Franck
    Brooks, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [37] Optimization of the CD123 CAR T-cell scFv for the treatment of patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Fredon, M.
    Poussard, M.
    Biichle, S.
    Anna, F.
    Bonnefoy, F.
    Bole-Richard, E.
    Renosi, F.
    Caumartin, J.
    Loustau, M.
    Adotevi, O.
    Saas, P.
    Angelot-Delettre, F.
    Galaine, J.
    Garnache-Ottou, F.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A37 - A37
  • [38] Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement
    Pemmaraju, Naveen
    Konopleva, Marina
    Sweet, Kendra
    Stein, Anthony S.
    Vasu, Sumithira
    Rizzieri, David A.
    Wang, Eunice S.
    Kantarjian, Hagop
    Brooks, Christopher L.
    Mughal, Tariq I.
    Lane, Andrew A.
    BLOOD, 2021, 138
  • [39] IMMUNOHISTOCHEMISTRY (CD123, CD56 AND CD4) REVEALS MINIMAL BONE MARROW INVOLVEMENT IN CASES OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
    Hwang, K.
    Park, C. J.
    Chi, H. S.
    Jang, S.
    Park, S. J.
    Huh, J. R.
    Lee, J. H.
    Suh, C.
    Lee, K. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 547 - 548
  • [40] Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial
    Pemmaraju, Naveen
    Konopleva, Marina
    Sweet, Kendra
    Stein, Anthony S.
    Vasu, Sumithira
    Rizzieri, David A.
    Wang, Eunice S.
    Kantarjian, Hagop
    Brooks, Christopher L.
    Paley, Carole
    Mughal, Tariq, I
    Lane, Andrew A.
    BLOOD, 2022, 140 : 6155 - 6157
12345